Cargando…
High-Throughput Drug Library Screening in Primary KMT2A-Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 Signaling
KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants (<1 year of age) represents an aggressive type of childhood leukemia characterized by a poor clinical outcome with a survival chance of <50%. Implementing novel therapeutic approaches for these patients is a slow-paced and costly p...
Autores principales: | Wander, Priscilla, Arentsen-Peters, Susan T. C. J. M., Vrenken, Kirsten S., Pinhanҫos, Sandra Mimoso, Koopmans, Bianca, Dolman, M. Emmy M., Jones, Luke, Garrido Castro, Patricia, Schneider, Pauline, Kerstjens, Mark, Molenaar, Jan J., Pieters, Rob, Zwaan, Christian Michel, Stam, Ronald W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945716/ https://www.ncbi.nlm.nih.gov/pubmed/35327440 http://dx.doi.org/10.3390/biomedicines10030638 |
Ejemplares similares
-
High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemia
por: Wander, Priscilla, et al.
Publicado: (2021) -
CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in KMT2A-Rearranged Acute Lymphoblastic Leukemia
por: Schneider, Pauline, et al.
Publicado: (2023) -
Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia
por: Schneider, Pauline, et al.
Publicado: (2023) -
Decitabine mildly attenuates MLL‐rearranged acute lymphoblastic leukemia in vivo, and represents a poor chemo‐sensitizer
por: Schneider, Pauline, et al.
Publicado: (2020) -
Irinotecan Induces Disease Remission in Xenograft Mouse Models of Pediatric MLL-Rearranged Acute Lymphoblastic Leukemia
por: Kerstjens, Mark, et al.
Publicado: (2021)